VC-backed technology company developing and delivering disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculousvirus vector expression systems (BVES) in insect cells.
Supported by a first in class Strategic Advisory Board combining investment and operational experience in developing and leading companies in animal and human health.
Two proprietary and patented technology platforms, Top-Bac® and CrisBio®, to respond to industry’s challenges in the production of biologicals: development time, scalability, versatility and cost.
Licenses and PoCs in various protein classes and indications across Animal Health, Human Health and Diagnostics.
We aim to transform protein production to allow universal access to biologics.
Single floor facility
Roughly 850m2 including administration, laboratory, rearing and production areas.
Around 3.5kg of recombinant protein/year, equivalent to antigen required to produce up to 100 million vaccine doses (dependent on protein and dose regiment)
GMP certification targeted H1 2021
AREAS OF FOCUS
20 years’ experience in the development and production of animal vaccines.
200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies.
First dossier for a veterinary vaccine produced using CrisBio® under review by EMA.
Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platformsLearn more
Chrysalises as natural production units for recombinant subu...
Algenex inaugura su nueva planta de fabricación de vacunas e...
Algenex raises €7.4 million in financing round